News | Radiopharmaceuticals and Tracers | July 01, 2019

Bracco Imaging Acquires Blue Earth Diagnostics

Transaction set to close in Q3 2019, bringing Axumin novel PET imaging agent into Bracco product portfolio

Bracco Imaging Acquires Blue Earth Diagnostics

July 1, 2019 — Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.

Bracco Imaging will acquire all outstanding shares of privately-held Blue Earth Diagnostics for the equity value of $450 million, plus closing adjustment estimated at $25 million, from healthcare company Syncona and Blue Earth Diagnostics' management team. Upon closing of the transaction, Blue Earth Diagnostics will be a subsidiary of Bracco Imaging, led by its current leadership team and will retain the Blue Earth Diagnostics name. Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140 million in the year to September 2019, primarily in the U.S.

The first novel positron emission tomography (PET) molecular imaging agent developed by Blue Earth Diagnostics is Axumin (F18-fluciclovine) injection. Axumin is approved in the U.S. and the European Union for PET imaging in men with suspected recurrent prostate cancer based on elevated prostate specific antigen (PSA) levels following prior treatment. The company's pipeline includes prostate specific membrane antigen (PSMA)-targeted radiohybrid ("rh") agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

Prostate cancer is the most common cancer in men, with an estimated number of more than 170 thousand new cases in 2019 in the U.S. While most cases of primary prostate cancer can be treated successfully, the cancer will recur in up to one third of cases and in a third of those recurrences, patients develop distant metastases leading to a fatal outcome. In two separate studies which evaluated the utility of Axumin (F18-fluciclovine) PET/CT (computed tomography) in providing physicians with actionable information for the management of men with recurrent prostate cancer, the intended management plan was changed for approximately 60 percent of the study subjects, based on the results of the Axumin PET/CT scan.

F18-fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology.

For more information: www.braccoimaging.com, www.blueearthdiagnostics.com

Related Content

FDA Clears AiCE Image Reconstruction on Canon's Aquilion Precision CT

Image courtesy of Canon Medical Systems

Technology | Computed Tomography (CT) | October 21, 2019
Canon Medical Systems USA Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance on its Advanced...
The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Selecting an AI Marketplace for Radiology: Key Considerations for Healthcare Providers
Feature | Artificial Intelligence | October 18, 2019 | Sanjay Parekh, Ph.D.
October 18, 2019 — As the nascent market for...
Surgical Institute of Reading Chooses RamSoft's PowerServer Lite PACS
News | PACS | October 18, 2019
Surgical Institute of Reading recently selected RamSoft’s PowerServer Lite PACS (picture archiving and communication...
MaxQ AI's Intracranial Hemorrhage Software to be Integrated on Philips CT Systems
News | Artificial Intelligence | October 18, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH...
Siemens Healthineers Announces First U.S. Install of Multix Impact Digital Radiography System
News | Digital Radiography (DR) | October 18, 2019
DHR Health in Edinburg, Texas, recently became the first healthcare facility in the United States to install the Multix...
USF Health Expands Digisonics System With Vascular Reporting
News | Cardiac PACS | October 17, 2019
University of South Florida (USF) Health in Tampa, Fla., has enhanced their use of the Digisonics Cardiovascular...
Sectra Adds DePuy Synthes 3-D Templates to Pre-Operative Orthopedic Solution
News | Orthopedic Imaging | October 17, 2019
International medical imaging information technology (IT) and cybersecurity company Sectra is extending its pre-...
Intelerad's nuage Patient Portal

Intelerad's nuage Patient Portal. Image courtesy of Intelerad.

News | Enterprise Imaging | October 17, 2019
Intelerad Medical Systems announced that OneWelbeck, a London operator of specialist facilities for minimally-invasive...
Carestream's Focus 35C digital radiography (DR) detector

The Focus 35C detector. Image courtesy of Carestream

News | Digital Radiography (DR) | October 17, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA), Dec. 1-6 in Chicago, Carestream will...